<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639547</url>
  </required_header>
  <id_info>
    <org_study_id>CTC-133</org_study_id>
    <nct_id>NCT01639547</nct_id>
  </id_info>
  <brief_title>Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C</brief_title>
  <official_title>A Randomized, Open-lable, Multicenter, Parallel Group Study to Compare SVR Rate of Pegasys Plus Ribavirin for 48 Weeks vs. 36 Weeks in Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of PEGASYS® (peginterferon alfa-2a 40KD)&#xD;
      plus Robatrol® (ribavirin) combination therapy given for 36 weeks versus 48 weeks on the&#xD;
      clearance of HCV viremia 24 weeks after treatment end&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pegylated interferon plus ribavirin brings a good therapeutic response and curability.&#xD;
      However, the adverse effects and sufferings are lots. Response-guided, personalized treatment&#xD;
      is current principle. In patients of CHC, GT1 PR treatment for 24 weeks is established in&#xD;
      rapid virologic responders (RVR) who have low viral load before treatment. As to patients&#xD;
      with RVR but high viral load (HVL), the treatment duration is 48 weeks that is the same as&#xD;
      patients with complete early virologic response (cEVR). Is a shorter duration of treatment&#xD;
      feasible for those with a good virokinetic response? The ideal treatment duration for&#xD;
      patients of chronic hepatitis C, GT-1, high viral load with RVR has had no enough data yet.&#xD;
      Is it really necessary to double the treatment duration (48 weeks) for patients of chronic&#xD;
      hepatitis C, GT-1, high viral load with RVR? Is 36-week adequate for them? A multicenter&#xD;
      trial of INDIV-2 was presented at EASL 2010. They treated CHC patients of naïve GT1 HVL and&#xD;
      RVR for 30 weeks and got similarly good SVR as those treated for 48 weeks (85% vs. 82%).&#xD;
&#xD;
      Therefore, investigators design a randomized controlled study to investigate the SVR rates&#xD;
      between treatment for 36 weeks and for 48 weeks in patients of CHC, GT1, HVL and RVR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    early termination due to difficult collection of patients&#xD;
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response</measure>
    <time_frame>At 24 weeks after end of treatment</time_frame>
    <description>Sustained virological response (SVR) defined as percentage of patients with HCV RNA &lt; 15 IU/ML as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test at 24 weeks post completion of the 36 or 48 week treatment periods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological Response Rate at week 2</measure>
    <time_frame>At treatment week 2</time_frame>
    <description>Virological Response Rate at week 2 defined as the percentage of patients with HCV RNA &lt; 15 IU/ML as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV at 2 weeks post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological response at end of treatment</measure>
    <time_frame>At end of treatment</time_frame>
    <description>Virological response at end of treatment defined as the percentage of patients with HCV RNA &lt; 15 IU/ML as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test after the last dose of study medication(± 28 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of virological response and SVR rate</measure>
    <time_frame>At 24 weeks after end of treatment</time_frame>
    <description>Correlation of virological response (HCV RNA &lt; 15 IU/ML) at week 2 and SVR rate in each group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">410</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>PEGASYS® plus ROBATROL® for 36 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PEGASYS® plus ROBATROL® for 48 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a plus Ribavirin</intervention_name>
    <description>Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks</description>
    <arm_group_label>PEGASYS® plus ROBATROL® for 36 weeks</arm_group_label>
    <arm_group_label>PEGASYS® plus ROBATROL® for 48 weeks</arm_group_label>
    <other_name>PEGASYS® plus ROBATROL®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20~70 years old&#xD;
&#xD;
          -  Patients have never been treated with traditional interferon plus ribavirin or&#xD;
             peginterferon plus ribarivin&#xD;
&#xD;
          -  Chronic hepatitis C, genotype 1, HCV-RNA &gt; 0.8x106 IU/ml, achieving RVR (undetectable&#xD;
             HCV RNA at week 4) in the SoC treatment&#xD;
&#xD;
          -  Patient must be able to comply with the assessments during the study&#xD;
&#xD;
          -  Compensated liver disease (Child-Pugh Grade A clinical classification for patients&#xD;
             with cirrhosis: total score ≦ 6)&#xD;
&#xD;
          -  All fertile males and females receiving ribavirin must be using two forms of effective&#xD;
             contraception during treatment with study drugs and 6 months post treatment completion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease,&#xD;
             alcoholic liver disease, toxin exposures)&#xD;
&#xD;
          -  History or other evidence of decompensated liver disease&#xD;
&#xD;
          -  Signs or symptoms of hepatocellular carcinoma&#xD;
&#xD;
          -  Co-infection with hepatitis A, hepatitis B or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Not adequately controlled thyroid dysfunction, diabetes mellitus (HbA1c &gt;8.5%) or&#xD;
             psychiatric disorders, especially depression. Severe psychiatric disease is defined as&#xD;
             treatment with an antidepressant medication or a major tranquilizer at therapeutic&#xD;
             doses for major depression or psychosis, respectively, for at least 3 months at any&#xD;
             previous time or any history of the following: a suicidal attempt, hospitalization for&#xD;
             psychiatric disease, or a period of disability due to a psychiatric disease&#xD;
&#xD;
          -  History of a severe seizure disorder or current anticonvulsant use&#xD;
&#xD;
          -  History of immunologically mediated disease, chronic pulmonary disease associated with&#xD;
             functional limitation, severe cardiac disease, major organ transplantation or other&#xD;
             evidence of severe illness, malignancy, or any other conditions which would make the&#xD;
             patient, in the opinion of the investigator, unsuitable for the study&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration) or clinically&#xD;
             relevant ophthalmological disorder (e.g. due to diabetes mellitus or hypertension)&#xD;
&#xD;
          -  Women with on-going pregnancy or breast feeding&#xD;
&#xD;
          -  Male partners of women who are pregnant&#xD;
&#xD;
          -  Subjects with any of the following laboratory abnormalities&#xD;
&#xD;
               -  Platelet count &lt; 90,000/mm3&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1,500 /mm3&#xD;
&#xD;
               -  Hemoglobin &lt; 12 g/dL (F), 13 g/dL (M)&#xD;
&#xD;
               -  Creatinine &gt; ULN&#xD;
&#xD;
               -  ALT and/or AST &gt; 10X ULN&#xD;
&#xD;
               -  Total serum bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          -  Inability or unwillingness to provide written informed consent or abide by the&#xD;
             requirements of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I-Shyan Sheen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linkou Medical Center, Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Show Chwan Memorial Hospital</name>
      <address>
        <city>Changhua City</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua County</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keelung Chang Gung Memorial Hospital</name>
      <address>
        <city>Keelung City</city>
        <zip>222</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tungs' Taichung MetroHarbor Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>435</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University - Shuang Ho Hospital</name>
      <address>
        <city>Taipei County</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkou Medical Center, Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>I-Shyan Sheen</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>PEGASYS® PLUS RIBAVIRIN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

